SCBMS
MCID: SZR027
MIFTS: 29

Seizures, Cortical Blindness, and Microcephaly Syndrome (SCBMS)

Categories: Eye diseases, Fetal diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Seizures, Cortical Blindness, and Microcephaly Syndrome

MalaCards integrated aliases for Seizures, Cortical Blindness, and Microcephaly Syndrome:

Name: Seizures, Cortical Blindness, and Microcephaly Syndrome 56 73 29 6
Scbms 56 73
Progressive Microcephaly-Seizures-Cortical Blindness-Developmental Delay Syndrome 58
Seizures, Cortical Blindness, Microcephaly Syndrome 56

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive

Miscellaneous:
onset of seizures in first months of life


HPO:

31
seizures, cortical blindness, and microcephaly syndrome:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases
Developmental anomalies during embryogenesis


Summaries for Seizures, Cortical Blindness, and Microcephaly Syndrome

OMIM : 56 Seizures, cortical blindness, and microcephaly syndrome (SCBMS) is an autosomal recessive neurodevelopmental disorder characterized by microcephaly, early-onset seizures, severely delayed psychomotor development, and cortical blindness. Affected individuals also tend to show poor overall growth with short stature (summary by Ercan-Sencicek et al., 2015). (616632)

MalaCards based summary : Seizures, Cortical Blindness, and Microcephaly Syndrome, is also known as scbms. An important gene associated with Seizures, Cortical Blindness, and Microcephaly Syndrome is DIAPH1 (Diaphanous Related Formin 1). The drugs Prucalopride and Lactulose have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are generalized hypotonia and seizures

UniProtKB/Swiss-Prot : 73 Seizures, cortical blindness, and microcephaly syndrome: A severe autosomal recessive neurodevelopmental disorder characterized by microcephaly, early-onset seizures, severely delayed psychomotor development, short stature, and cortical blindness.

Related Diseases for Seizures, Cortical Blindness, and Microcephaly Syndrome

Symptoms & Phenotypes for Seizures, Cortical Blindness, and Microcephaly Syndrome

Human phenotypes related to Seizures, Cortical Blindness, and Microcephaly Syndrome:

31 (show all 8)
# Description HPO Frequency HPO Source Accession
1 generalized hypotonia 31 occasional (7.5%) HP:0001290
2 seizures 31 HP:0001250
3 short stature 31 HP:0004322
4 microcephaly 31 HP:0000252
5 optic atrophy 31 HP:0000648
6 poor speech 31 HP:0002465
7 hypoplasia of the corpus callosum 31 HP:0002079
8 cerebral visual impairment 31 HP:0100704

Symptoms via clinical synopsis from OMIM:

56
Neurologic Central Nervous System:
seizures
poor speech
hypoplasia of the corpus callosum
delayed psychomotor development, moderate to severe

Head And Neck Eyes:
optic atrophy
cortical blindness

Muscle Soft Tissue:
hypotonia (in some patients)

Growth Height:
short stature

Growth Other:
poor growth

Head And Neck Head:
microcephaly (up to -10 sd)

Clinical features from OMIM:

616632

Drugs & Therapeutics for Seizures, Cortical Blindness, and Microcephaly Syndrome

Drugs for Seizures, Cortical Blindness, and Microcephaly Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prucalopride Approved Phase 4 179474-81-8
2
Lactulose Approved Phase 4 4618-18-2 11333
3 Cathartics Phase 4
4 Gastrointestinal Agents Phase 4
5 Neurotransmitter Agents Phase 4
6 Laxatives Phase 4
7 Serotonin Agents Phase 4
8 Serotonin Receptor Agonists Phase 4
9
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Multicenter, Single-Arm, Interventional, Phase 4 Study to Evaluate the Efficacy and Safety of Prucalopride in Combination With PEG or Lactulose in Women With Chronic Constipation (CC) Completed NCT02228616 Phase 4 Prucalopride;Polyethylene glycol (PEG);Lactulose
2 A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prucalopride (Resolor) Tablets in Participants With Chronic Constipation Completed NCT01116206 Phase 3 Prucalopride;Placebo

Search NIH Clinical Center for Seizures, Cortical Blindness, and Microcephaly Syndrome

Genetic Tests for Seizures, Cortical Blindness, and Microcephaly Syndrome

Genetic tests related to Seizures, Cortical Blindness, and Microcephaly Syndrome:

# Genetic test Affiliating Genes
1 Seizures, Cortical Blindness, and Microcephaly Syndrome 29 DIAPH1

Anatomical Context for Seizures, Cortical Blindness, and Microcephaly Syndrome

MalaCards organs/tissues related to Seizures, Cortical Blindness, and Microcephaly Syndrome:

40
Eye

Publications for Seizures, Cortical Blindness, and Microcephaly Syndrome

Articles related to Seizures, Cortical Blindness, and Microcephaly Syndrome:

(show all 11)
# Title Authors PMID Year
1
Homozygous loss of DIAPH1 is a novel cause of microcephaly in humans. 56 6
24781755 2015
2
Novel loss-of-function variants in DIAPH1 associated with syndromic microcephaly, blindness, and early onset seizures. 6
26463574 2016
3
Efficacy and safety of acupuncture for functional constipation: a randomised, sham-controlled pilot trial. 61
29903020 2018
4
Endothelin-1 mediated induction of extracellular matrix genes in strial marginal cells underlies strial pathology in Alport mice. 61
27553900 2016
5
Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. 61
27056037 2016
6
A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. 61
25808103 2015
7
A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. 61
25869393 2015
8
Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies. 61
25273116 2014
9
Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment. 61
23480216 2013
10
Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. 61
22882724 2012
11
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. 61
19035970 2009

Variations for Seizures, Cortical Blindness, and Microcephaly Syndrome

ClinVar genetic disease variations for Seizures, Cortical Blindness, and Microcephaly Syndrome:

6 (show top 50) (show all 81) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 DIAPH1 NM_005219.5(DIAPH1):c.2769del (p.Phe923fs)deletion Pathogenic 217753 rs863225242 5:140908748-140908748 5:141529181-141529181
2 DIAPH1 NM_005219.5(DIAPH1):c.3145C>T (p.Arg1049Ter)SNV Pathogenic 217754 rs863225243 5:140908023-140908023 5:141528456-141528456
3 DIAPH1 GRCh37/hg19 5q31.3(chr5:140953993-140992629)copy number loss Pathogenic 625826 5:140953993-140992629
4 DIAPH1 NM_005219.5(DIAPH1):c.2332C>T (p.Gln778Ter)SNV Pathogenic/Likely pathogenic 183344 rs730882242 5:140953085-140953085 5:141573518-141573518
5 DIAPH1 NM_005219.5(DIAPH1):c.627C>A (p.Tyr209Ter)SNV Likely pathogenic 522646 rs369494682 5:140961936-140961936 5:141582369-141582369
6 DIAPH1 NM_005219.5(DIAPH1):c.77dup (p.Pro27fs)duplication Likely pathogenic 800526 5:140998404-140998405 5:141618837-141618838
7 DIAPH1 NM_005219.5(DIAPH1):c.1821_1823TCC[8] (p.Pro618_Pro620del)short repeat Conflicting interpretations of pathogenicity 593399 rs3075570 5:140953564-140953572 5:141573997-141574005
8 DIAPH1 NM_005219.5(DIAPH1):c.2772C>T (p.Gly924=)SNV Conflicting interpretations of pathogenicity 582965 rs779376542 5:140908745-140908745 5:141529178-141529178
9 DIAPH1 NM_005219.5(DIAPH1):c.2224C>G (p.Pro742Ala)SNV Conflicting interpretations of pathogenicity 542364 rs199749212 5:140953193-140953193 5:141573626-141573626
10 DIAPH1 NM_005219.4(DIAPH1):c.3439-3deldeletion Conflicting interpretations of pathogenicity 475707 rs1335130331 5:140905743-140905743 5:141526176-141526176
11 DIAPH1 NM_005219.5(DIAPH1):c.2158C>T (p.Leu720Phe)SNV Conflicting interpretations of pathogenicity 450432 rs200606811 5:140953259-140953259 5:141573692-141573692
12 DIAPH1 NM_005219.5(DIAPH1):c.2099T>A (p.Ile700Asn)SNV Uncertain significance 475701 rs199830182 5:140953318-140953318 5:141573751-141573751
13 DIAPH1 NM_005219.5(DIAPH1):c.1269C>G (p.Asp423Glu)SNV Uncertain significance 475696 rs367981585 5:140957053-140957053 5:141577486-141577486
14 DIAPH1 NM_005219.5(DIAPH1):c.1964C>A (p.Pro655His)SNV Uncertain significance 351292 rs367669306 5:140953453-140953453 5:141573886-141573886
15 DIAPH1 NM_005219.5(DIAPH1):c.2162C>A (p.Pro721His)SNV Uncertain significance 351289 rs373520931 5:140953255-140953255 5:141573688-141573688
16 DIAPH1 NM_005219.5(DIAPH1):c.3313C>T (p.Arg1105Trp)SNV Uncertain significance 444663 rs781577050 5:140905989-140905989 5:141526422-141526422
17 DIAPH1 NM_005219.5(DIAPH1):c.3358G>A (p.Glu1120Lys)SNV Uncertain significance 475706 rs756003432 5:140905944-140905944 5:141526377-141526377
18 DIAPH1 NM_005219.5(DIAPH1):c.2107C>G (p.Pro703Ala)SNV Uncertain significance 228575 rs201433617 5:140953310-140953310 5:141573743-141573743
19 DIAPH1 NM_005219.5(DIAPH1):c.3230C>G (p.Pro1077Arg)SNV Uncertain significance 163067 rs376593325 5:140907183-140907183 5:141527616-141527616
20 DIAPH1 NM_005219.5(DIAPH1):c.3050T>C (p.Met1017Thr)SNV Uncertain significance 178340 rs376220834 5:140908118-140908118 5:141528551-141528551
21 DIAPH1 NM_005219.5(DIAPH1):c.1364G>A (p.Arg455Gln)SNV Uncertain significance 163074 rs200004048 5:140956355-140956355 5:141576788-141576788
22 DIAPH1 NM_005219.5(DIAPH1):c.3003C>G (p.Ile1001Met)SNV Uncertain significance 475705 rs1554201371 5:140908284-140908284 5:141528717-141528717
23 DIAPH1 NM_005219.5(DIAPH1):c.3701C>T (p.Ala1234Val)SNV Uncertain significance 475709 rs764739820 5:140896536-140896536 5:141516969-141516969
24 DIAPH1 NM_005219.5(DIAPH1):c.2009C>T (p.Pro670Leu)SNV Uncertain significance 475700 rs751847293 5:140953408-140953408 5:141573841-141573841
25 DIAPH1 NM_005219.5(DIAPH1):c.3051G>A (p.Met1017Ile)SNV Uncertain significance 504567 rs373275414 5:140908117-140908117 5:141528550-141528550
26 DIAPH1 NM_005219.5(DIAPH1):c.3811G>T (p.Ala1271Ser)SNV Uncertain significance 542357 rs1167599945 5:140896426-140896426 5:141516859-141516859
27 DIAPH1 NM_005219.5(DIAPH1):c.1821_1823TCC[14] (p.Pro618_Pro620dup)short repeat Uncertain significance 542361 rs3075570 5:140953563-140953564 5:141573996-141573997
28 DIAPH1 NM_005219.5(DIAPH1):c.3809G>A (p.Arg1270His)SNV Uncertain significance 542360 rs371664456 5:140896428-140896428 5:141516861-141516861
29 DIAPH1 NM_005219.5(DIAPH1):c.2424C>A (p.Asn808Lys)SNV Uncertain significance 577243 rs766731479 5:140951542-140951542 5:141571975-141571975
30 DIAPH1 NM_005219.5(DIAPH1):c.1848_1862del (p.Pro618_Pro622del)deletion Uncertain significance 566485 rs1562320961 5:140953555-140953569 5:141573988-141574002
31 DIAPH1 NM_005219.5(DIAPH1):c.1639G>C (p.Glu547Gln)SNV Uncertain significance 581935 rs1317819365 5:140954536-140954536 5:141574969-141574969
32 DIAPH1 NM_005219.5(DIAPH1):c.259G>A (p.Val87Ile)SNV Uncertain significance 569503 rs368889655 5:140966650-140966650 5:141587083-141587083
33 DIAPH1 NM_005219.5(DIAPH1):c.1748C>G (p.Pro583Arg)SNV Uncertain significance 542358 rs201719002 5:140953669-140953669 5:141574102-141574102
34 DIAPH1 NM_005219.5(DIAPH1):c.3727A>G (p.Met1243Val)SNV Uncertain significance 542362 rs1554199642 5:140896510-140896510 5:141516943-141516943
35 DIAPH1 NM_005219.5(DIAPH1):c.3406A>T (p.Met1136Leu)SNV Uncertain significance 542356 rs1554200929 5:140905896-140905896 5:141526329-141526329
36 DIAPH1 NM_005219.5(DIAPH1):c.3097G>A (p.Asp1033Asn)SNV Uncertain significance 542359 rs1303934222 5:140908071-140908071 5:141528504-141528504
37 DIAPH1 NM_005219.5(DIAPH1):c.2602C>T (p.Arg868Cys)SNV Uncertain significance 542363 rs1554201531 5:140909244-140909244 5:141529677-141529677
38 DIAPH1 NM_005219.5(DIAPH1):c.2107C>T (p.Pro703Ser)SNV Uncertain significance 548628 rs201433617 5:140953310-140953310 5:141573743-141573743
39 DIAPH1 NM_005219.5(DIAPH1):c.2354C>T (p.Ser785Phe)SNV Uncertain significance 572032 rs532205362 5:140953063-140953063 5:141573496-141573496
40 DIAPH1 NM_005219.5(DIAPH1):c.217G>A (p.Ala73Thr)SNV Uncertain significance 575565 rs184081055 5:140966692-140966692 5:141587125-141587125
41 DIAPH1 NM_005219.5(DIAPH1):c.3157G>A (p.Glu1053Lys)SNV Uncertain significance 575625 rs1003389476 5:140907256-140907256 5:141527689-141527689
42 DIAPH1 NM_005219.5(DIAPH1):c.2800C>T (p.Arg934Trp)SNV Uncertain significance 573683 rs200688040 5:140908487-140908487 5:141528920-141528920
43 DIAPH1 NM_005219.5(DIAPH1):c.2668A>G (p.Met890Val)SNV Uncertain significance 574584 rs200251893 5:140909178-140909178 5:141529611-141529611
44 DIAPH1 NM_005219.5(DIAPH1):c.1280+3A>GSNV Uncertain significance 583322 rs747583916 5:140957039-140957039 5:141577472-141577472
45 DIAPH1 NM_005219.5(DIAPH1):c.724C>G (p.Leu242Val)SNV Uncertain significance 568520 rs766359994 5:140960411-140960411 5:141580844-141580844
46 DIAPH1 NM_005219.5(DIAPH1):c.3486G>A (p.Met1162Ile)SNV Uncertain significance 578439 rs747116749 5:140905693-140905693 5:141526126-141526126
47 DIAPH1 NM_005219.5(DIAPH1):c.3175C>G (p.Leu1059Val)SNV Uncertain significance 578663 rs200394036 5:140907238-140907238 5:141527671-141527671
48 DIAPH1 NM_005219.5(DIAPH1):c.1821_1823TCC[16] (p.Pro616_Pro620dup)short repeat Uncertain significance 568618 rs3075570 5:140953563-140953564 5:141573996-141573997
49 DIAPH1 NM_005219.5(DIAPH1):c.3767C>T (p.Thr1256Ile)SNV Uncertain significance 655958 5:140896470-140896470 5:141516903-141516903
50 DIAPH1 NM_005219.5(DIAPH1):c.3322C>T (p.His1108Tyr)SNV Uncertain significance 655416 5:140905980-140905980 5:141526413-141526413

Expression for Seizures, Cortical Blindness, and Microcephaly Syndrome

Search GEO for disease gene expression data for Seizures, Cortical Blindness, and Microcephaly Syndrome.

Pathways for Seizures, Cortical Blindness, and Microcephaly Syndrome

GO Terms for Seizures, Cortical Blindness, and Microcephaly Syndrome

Sources for Seizures, Cortical Blindness, and Microcephaly Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....